Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 19, Art. 59 (pp. 800-818)    |    2018       

»

Hyperuricemia and its role in the development of cardiovascular diseases and type 2 diabetes

Salukhov V.V.,1 Kalinina L.V.,2 Katselnik E.Yu.2,3

1S.M. Kirov Military Medical Academy, Saint Petersburg, Russia
2International Medical Center "SOGAZ", Saint Petersburg, Russia
3Saint Petersburg State University, Russia

Brief summary

In recent years, researchers have focused on the potential role of hyperuricemia (HU) as a risk factor for a whole range of conditions, such as arterial hypertension, atherosclerosis, overweight, dyslipidemia, metabolic syndrome, or type 2 diabetes. Despite the fact that some researches do not detect a strong correlation between HU and an increased risk of CVD, a sufficient amount of scientific evidence has been gathered as to the significance of uric acid (UA) in predicting CVD and the development of other risk factors, which can be concerned with even a slight increase in the UA level. The target level of UA remains uncertain; the place of hypouricemia in the cardiovascular disease continuum also needs further investigation. Due to the non-reproducibility of data, today genetic research is rather of scientific interest than of the clinical one, nevertheless this direction can also have good prospects in the prevention, diagnostics, and forecasting the gravity of the course of many chronic conditions.


Key words

uric acid, hyperuricemia, atherosclerosis, metabolic syndrome, diabetes mellitus

Reference list

1. Carella, A.M. Hyperuricemia and global Cardiovascular Risk: State of the art and preventive prospects. / A.M. Carella, T. Marinelli, A. Melfitano et al. // Archives of Preventive Medicine. - 2017. - Vol. 2 (1). - P. 22-27. doi: 10.17352/apm.000008


2. Masseoud, D. Overview of hyperuricaemia and gout. / D. Masseoud, K. Rott, R. Liu-Bryan et al. // Curr Pharm Des. - 2005. - Vol 11. - P. 4117-4124. doi: 10.2174/138161205774913318


3. Richette, P. Gout. / P. Richette, T. Bardin // Lancet. - 2010. - Vol. 375. - P. 318-328. doi:10.1016/S0140-6736(09)60883-7


4. Marangella, M. Uric acid elimination in the urine. Pathophysiological implications. / M. Marangella // Contrib Nephrol. - 2005. - Vol. 147. - P. 132-148. doi:10.1159/000082551


5. So, A. Uric acid transport and disease. / A. So, B. Thorens. // The Journal of Clinical Investigation. - 2010. - Vol.120 (6). - P. 1791-1799. doi:10.1172/JCI42344


6. Feig, D. Uric Acid and Cardiovascular Risk. / D. Feig, D.H. Kang, R.J. Johnson. // N Engl J Med. - 2008. - Vol. 359. - P. 1811-1821 doi: 10.1056/NEJMra0800885


7. Culleton B.F. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. [Elektronnii resyrs] / B.F. Culleton B.F., Larson M.G., Kannel W.B. et al. // Ann Intern Med. - 1999. - Vol. 131. - P. 7-13. - Rejim dostypa: https://www.ncbi.nlm.nih.gov/pubmed/10391820.


8. Fang, J. Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992. [Elektronnii resyrs] / J. Fang, M.H. Alderman // JAMA. - 2000. - Vol. 283. - P. 2404-2410. - Rejim dostypa: https://jamanetwork.com/journals/jama/fullarticle/192685


9. Kim, S. Y. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. / S.Y. Kim, J.P. Guevara, K.M. Kim et al. // Arthritis care & research. - 2010. - Vol. 62(2). - P. 170-180. doi:10.1002/acr.20065


10. Zhao, G. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. / G. Zhao, L. Huang, M. Song, Y. Song // Atherosclerosis. - 2010. - Vol. 231(1). - P. 61-68. doi:10.1016/j.atherosclerosis.2013.08.023


11. Benjamin, E. J. Heart disease and stroke statistics. / E.J. Benjamin, M.J. Blaha, S.E. Chiuve et al. // Circulation. - 2017. - Vol. 135 (10). - P. 146-603. doi: 10.1161/CIR.0000000000000485


12. Kiss, L. Z. Serum Uric Acid Is Independently Associated with Coronary Calcification in an Asymptomatic Population / L.Z. Kiss, Z. Bagyura, C. Csobay-Novák et al. // J. of Cardiovasc. Trans. Res. - 2018. - doi:10.1007/s12265-018-9843-8


13. Nomura, J. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. / J. Nomura, N. Busso, A. Ives et al. // Scientific Reports. - 2014. - Vol. 4. - P. 4554. doi: 10.1038/srep04554


14. Cai, H. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. / H. Cai, D.G. Harrison // Circulation Research. - 2000. - Vol. 87, N. 10. - P. 840-844. doi: 10.1161/01.RES.87.10.840


15. Kushiyama, A. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. / A. Kushiyama, H. Okubo, H. Sakoda et al. // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2012. - Vol. 32, no. 2. - P. 291-298. doi:10.1161/ATVBAHA.111.234559


16. Moore, K.J. Macrophages in atherosclerosis: a dynamic balance. / K.J. Moore, F.J. Sheedy, E.A. Fisher // Nature Reviews Immunology. - 2013. - Vol. 13, no. 10. - P. 709-721. doi: 10.1038/nri3520


17. Maruhashia, T. Hyperuricemia and endothelial function: From molecular background to clinical perspectives / T. Maruhashia, I. Hisatomeb, Y. Kiharaa et al. Hyperuricemia // Atherosclerosis. - 2018. - Vol. 238. - P. 226-331. doi: 10.1016/j.atherosclerosis.2018.10.007


18. Mishima, M. Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents. / M. Mishima, T. Hamada, N. Maharani et al. // Drug Research. - 2016. - Vol. 66, no. 05. - P. 270-274. doi: 10.1055/s-0035-1569405


19. Khosla, U. M. Hyperuricemia induces endothelial dysfunction. / U.M. Khosla, S. Zharikov, Finch J.L. et al. // Kidney International. - 2005. - Vol. 67, no. 5. - P. 1739-1742. doi: 10.1111/j.1523-1755.2005.00273.x


20. Corry, D.B. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular reninangiotensin system. / D.B. Corry, P. Eslami, K. Yamamoto et al // Journal of Hypertension. - 2008. - Vol. 26, no. 2. - P. 269-275. doi: 10.1161/HYPERTENSIONAHA.116.08114


21. Freedman, D.S. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I epidemiologic follow-up study. [Elektronnii resyrs] / D.S Freedman, D.F. Williamson, E.W. Gunter et al. // Am J Epidemiol. - 1995. - Vol. 141. - P. 637 - 644. - Rejim dostypa: https://www.ncbi.nlm.nih.gov/pubmed/7702038.


22. Wheeler, J.G. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. / J.G. Wheeler, K.D. Juzwishin, G. Eiriksdottir et al. // PLOS Medicine. - 2005. - Volume 2 (3). - P. 236-243. doi:10.1371/journal.pmed.0020076


23. Morbidoni, L. Gout, hyperuricemia and cardiovascular risk. / L. Morbidoni, D. Olivari // Italian Journal of Medicine. - 2018. - Vol. 12 (3). - P. 190-202. doi:10.4081/itjm.2018.1011


24. Venishetty, S. Serum Uric Acid Levels in Type 2 Diabetes Mellitus: Is There a Linear Relationship with Severity of Carotid Atherosclerosis? / R. Bhat, S. Venishetty, Kv Rajagopal // Rajagopal Indian J Endocrinol Metab. - 2018. - Vol. 22 (5). - P. 678-682. doi: 10.4103/ijem.IJEM_641_17


25. Devries, S. Influence of age and gender on the presence of coronary calcium detected by ultrafast computed tomography. / S. Devries, C. Wolfkiel, B. Fusman et al. // J Am Coll Cardiol. - 1995. - Vol. 25. - P. 76 - 82. doi: 10.1016/0735-1097(94)00342-N


26. Loria, C.M. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. / C.M. Loria, K. Liu, C.E. Lewis et al. // J Am Coll Cardiol. - 2007. - Vol. 49. - P. 2013-2020. doi: 10.1016/j.jacc.2007.03.009.


27. Krishnan, E. Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study. / E.Krishnan, B.J. Pandya, L. Chung et al. // Arthritis Res Ther. - 2011. - Vol. 13 (2). - P. 66. doi: 10.1186/ar3322


28. Larsen, T. R. The association between uric acid levels and different clinical manifestations of coronary artery disease. / T.R. Larsen, O. Gerko, A.C.P. Diederichsen et al. // Coronary Artery Disease. - 2018. - Vol. 29 (3). - P. 194-203. doi: 10.1097/MCA.0000000000000593


29. Li, Q. The Association between Serum Uric Acid Levels and the Prevalence of Vulnerable Atherosclerotic Carotid Plaque: A Cross-sectional Study. / Q. Li, Y. Zhou, K. Dong // Sci. Rep. - 2015. - Vol. 5. - P. 10003. doi: 10.1038/srep10003


30. Giambelluca, A. Correlation between uric acid, metabolic syndrome and carotid atherosclerosis in a cohort of elderly outpatients. / A. Giambelluca, A. Tafa, C. Caffarelli et al // Arterioscler Thromb Vasc Biol. - 2005. - Vol. 25 (5). - P. 1038-1044. doi: 10.1161/01.ATV.0000161274.87407.26


31. Hall, A.P. Epidemiology of gout and hyperuricemia. / A.P. Hall, P.E. Barry, T.R. Dawber, P.M. McNamara. // The American Journal of Medicine. - 1967. - Vol. 42 (1). - P. 27-37. doi: 10.1016/0002-9343(67)90004-6


32. Segal, M.S. Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index? / M.S. Segal, E. Gollub, R.J. Johnson // Eur J Nutr. - 2007. -Vol. 46. - P. 406-417. DOI: 10.1007/s00394-007-0680-9


33. Wu, Y.T. Serum uric acid and islet β-cell function in patients with pre-diabetes and type 2 diabetes mellitus. [Elektronnii resyrs] / Y.T. Wu, H. He, X. Wang et al. // Sichuan Da Xue Xue Bao Yi Xue Ban. - 2018. - Vol. 49(1). - P. 69 - 73. - Rejim dostypa: https://www.ncbi.nlm.nih.gov/pubmed/29737093.


34. Takir, M. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. / M. Takir, O. Kostek, A. Ozkok et al. // J Investig Med. - 2015. - Vol. 63 (8). - P. 924-929. doi: 10.1097/JIM.0000000000000242.


35. Haneklaus, M. NLRP3 at the interface of metabolism and inflammation. / M. Haneklaus, L.A. O?Neill. // Immunological Reviews. - 2015. - Vol. 265 (1). - P. 53-62. doi: 10.1111/imr.12285.


36. Czemplik, M. Therapeutic strategies of plant-derived compounds for diabetes via regulation of monocyte chemoattractant protein-1. / M. Czemplik, A. Kulma, Y.F. Wang et al. // Curr Med Chem. - 2017. - Vol. 24 (14). - P. 1453-1468. doi: 10.2174/0929867324666170303162935.


37. Lin, Y. Short-term insulin intensive therapy decreases MCP1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newly diagnosed type 2 diabetics. / Y. Lin, S. Ye, Y. He et al. // Arch Endocrinol Metab. - 2018. - Vol. 62 (2). - P. 212-220. doi: 10.20945/2359-3997000000029.


38. Kou, H. Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults. / H. Kou, J. Deng, D. Gao et al. // Clin Exp Hypertens. - 2018. - Vol. 40 (7). - P. 656-663. doi: 10.1080/10641963.2018.1425414.


39. Kodama, S. Association between serum uric acid and development of type 2 diabetes. / S. Kodama, K. Saito, Y. Yachi et al. // Diabetes Care. - 2009. - Vol. 32. - P. 1737-1742. doi: 10.2337/dc09-0288


40. Lv, Q. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. / Q. Lv, X.F. Meng, F.F. He et al. // PLoS One. - 2013. - Vol. 8. - P. 56864. doi: 10.1371/journal.pone.0056864.


41. Bombelli, M. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study. / M. Bombelli, F. Quarti-Trevano, . Tadic et al. // J Hypertens. - 2018. - Vol. 36(7). - P. 1492-1498. doi: 10.1097/HJH.0000000000001721.


42. Xu, Y. Hyperuricemia as an Independent Predictor of Vascular Complications and Mortality in Type 2 Diabetes Patients: A Meta-Analysis. / Y. Xu, J. Zhu, L. Gao et al. // PLoS one. - 2013. - Vol. 8(10). - P. 78206. doi: 10.1371/journal.pone.0078206


43. Qin, L. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. / L. Qin, Y. Zhen, L. Bin et al // Cardiovasc Diabetol. - 2011. - V. 10. - P. 72. doi: 10.1186/1475-2840-10-72


44. Meena, R. Plasma Uric Acid Levels in Patients with Diabetes Mellitus and Impaired Glucose Tolerance Test in Comparison with Normal Subjects. / R. Meena, S.R. Meena // International Journal of Science and Research. - 2016. - Vol. 5 (2). - P. 2090-2093.


45. Bo, S. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. / S. Bo, P. Cavallo-Perin, L. Gentile et al. // Eur J Clin Invest. - 2001. - Vol. 31(4). - P. 318-321. doi.org/10.1046/j.1365-2362.2001.00812.x


46. Duman, T.T. Serum Uric acid is correlated with HbA1c levels in type 2 diabetes mellitus. / T.T. Duman, M.Z. Kocak, B.M. Atak et al. // Exp Biomed Res. - 2018. - Vol. 1 (1). - P. 6-9. Doi: 10.30714/j-ebr.2018136918


47. Atak, B.M. Serum uric acid level is associated with type 2 diabetes mellitus and diabetic regulation. / B.M. Atak, T.T. Duman, M.Z. Mehmet et al. // Exp Biomed Res. - 2018. - Vol. 1 (4). - P. 135-139 doi: 10.30714/j-ebr.2018443416


48. Woyesa, S.B. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa university comprehensive specialized hospital, South West Ethiopia. / S.B. Woyesa, T.A. Hirigo, T.B. Wube // BMC Endocrine Disorders. - 2017. - Vol. 17 (76). - P. 1-8. doi: 10.1186/s12902-017-0226-y


49. Neupane, S. Association between serum uric acid, urinary albumin excretion, and glycated hemoglobin in Type 2 diabetic patient. / S. Neupane, R.K. Dubey, N. Gautam et al. // Niger Med J. - 2016. - Vol. 57. - P. 119-123. doi: 10.4103/0300-1652.182074.


50. Cicero, A.F.G. Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study. / A.F.G. Cicero, M. Rosticci, F. Fogacci et al. // Eur J Intern Med. - 2017. - Vol. 37. - P. 38-42. doi: 10.1016/j.ejim.2016.07.026.


51. Kojanova, T.V. Geneticheskaya predraspolojennost k razvitiu ateroskleroza. / T.V. Kojanova, E.V. Neydahin, S.S Jilina i dr. // Arhiv vnytrennei medicini. - 2018. - T. 8, ? 6. - S. 407-417. doi: 10.20514/2226-67042018-8-6-407-417


52. Romanova, A.N. Geneticheskie markeri metabolicheskogo sindroma koronarnogo ateroskleroza y jitelei Yakytii. / A.N. Romanova, M.I. Voevoda, V.N. Maksimov // Rossiiskii kardiologicheskii jyrnal. 2017. Tom 10, nomer 150. Str. 66-75. doi: 10.15829/1560-4071-2017-10-66-75


53. Yamada, Y. Identification of four genes as novel susceptibility loci for early-onset type 2 diabetes mellitus, metabolic syndrome, or hyperuricemia. / Y. Yamada, K. Kato, M. Oguri et al. // Biomed Rep. 2018. Vol. 9, is.1. P. 21 - 36. doi: 10.3892/br.2018.1105